Phaseline

Companies › Akeso

Akeso: clinical trials, targets and expected readouts

14 active drug programs in 196 registered trials: 112 Phase 2, 52 Phase 1, 31 Phase 3, 1 Phase 4; Oncology, Other, Infectious disease, Hematology; next expected readout Nov 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Cadonilimab (AK104)
Programmed cell death protein 1 inhibitor; Cytotoxic T-lymphocyte protein 4 inhibitor
PDCD1, CTLA4Phase 3Hepatocellular Carcinoma; Cervical Cancer; Gastric and Gastroesophageal Junction Adenocarcinoma; NSCLC (Non-small Cell Lung Cancer) …Nov 2026
pulocimab (AK109)
PD-L2 monoclonal antibody
PD-L2Phase 3Gastric and Gastroesophageal Junction Adenocarcinoma; Gastric Adenocarcinoma and Gastroesophageal Junction Adenocarcinoma; Advanced Solid TumorNov 2026
Envafolimab (AK112)
Programmed cell death 1 ligand 1 binding agent
CD274Phase 3Triple-Negative Breast Cancer (TNBC); Advanced Squamous Non Small Cell Lung Cancer; Advanced Non-small-cell Lung Cancer; Colorectal Adenocarcinoma …Dec 2026
Penpulimab (AK105)
Programmed cell death protein 1 inhibitor
PDCD1Phase 3Nasopharyngeal CarcinomaDec 2026
AK117
anti-CD47 antibody
CD47Phase 3Head and Neck Squamous Cell Carcinoma; Higher-risk Myelodysplastic Syndromes; Metastatic Triple-negative Breast Cancer; Resectable Gastric or Gastroesophageal Junction Adenocarcinoma …Dec 2026
AK112 (Ivonescimab)
Dual PD-1/TIGIT bispecific antibody
PDCD1, VEGFAPhase 3Pancreatic Cancer; Non-Small Cell Lung Cancer; Platinum-sensitive Ovarian Cancer; Extensive-stage Small Cell Lung Cancer (ES-SCLC)May 2027
AK146D1
Anti-Trop2/Nectin4 bispecific antibody-drug conjugate
TROP2, NECTIN4Phase 2Advanced Non Small Cell Lung Cancer (NSCLC); Advanced Breast Cancer; Advanced Solid TumorsMay 2027
AK130
Bispecific antibody
–Phase 2Pancreatic Cancer; Biliary Tract Cancer; Hepatocellular CarcinomaMay 2027
AK119
anti-CD73 monoclonal antibody
NT5EPhase 1Colorectal Cancer; Solid Tumor, AdultDec 2026
AK129
Bispecific antibody targeting LAG-3 and PD-1
LAG3, PDCD1Phase 1Advanced Malignant Tumors(Stage IA-IB); Non-small Cell Lung Cancer Stage IIIB/IV; Classic Hodgkin LymphomaDec 2026
AK138D1–Phase 1Solid Cancer; Non-Small Cell Lung CancerFeb 2028
AK127
Bispecific antibody
–Phase 1Advanced Malignant Tumors; Advanced Solid Tumors; Hepatocellular CarcinomaSep 2028
AK131
anti-PD-1 and CD73 bispecific antibody
PDCD1, NT5EPhase 1Solid TumorDec 2028
AK157D1 for injection–Phase 1Advanced Solid TumorsMar 2029

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05319431Cadonilimab (AK104)Phase 2Unresectable, Non-metastatic Hepatocellular CarcinomaOncologyAug 2023
NCT06532591Cadonilimab (AK104)Phase 2NSCLCOncologyApr 2025
NCT05859750Cadonilimab (AK104)Phase 2Pancreatic CancerOncologyJun 2025
NCT05824481Cadonilimab (AK104)Phase 2Endometrial CancerOncologyJul 2025
NCT04980885AK117Phase 1Acute Myeloid LeukemiaOncologySep 2025
NCT04900350AK117Phase 1Myelodysplastic SyndromeHematologySep 2025
NCT06371157Cadonilimab (AK104)Phase 3Hepatocellular CarcinomaOncologyOct 2025
NCT04982237Cadonilimab (AK104)Phase 3Cervical CancerOncologyDec 2025
NCT05685550Envafolimab (AK112)Phase 2Progression Free Survival(PFS)OtherDec 2025
NCT06035224Cadonilimab (AK104)Phase 2Clear Cell Renal Cell CarcinomaOncologyJan 2026
NCT06196203AK117Phase 2Higher-risk Myelodysplastic SyndromesHematologyJan 2026
NCT06809517Envafolimab (AK112)Phase 1Leptomeningeal MetastasisOncologyMar 2026
NCT05868876Cadonilimab (AK104)Phase 1Advanced Malignant TumorsOncologyMar 2026
NCT05868876AK127Phase 1Advanced Malignant TumorsOncologyMar 2026
NCT07340476Envafolimab (AK112)Phase 1Healthy Male SubjectsOtherApr 2026
NCT05808608Cadonilimab (AK104)Phase 1Renal Cell CarcinomaOncologyApr 2026
NCT05951608Envafolimab (AK112)Phase 1Advanced Solid TumorsOncologyMay 2026
NCT06654011Cadonilimab (AK104)Phase 2Cervical AdenocarcinomaOncologyMay 2026
NCT05951608AK127Phase 1Advanced Solid TumorsOncologyMay 2026
NCT05846867Envafolimab (AK112)Phase 1Colorectal CancerOncologyMay 2026
NCT05846867AK119Phase 1Colorectal CancerOncologyMay 2026
NCT05932212Cadonilimab (AK104)Phase 2Vulvar CancerOncologyMay 2026
NCT05645276AK129Phase 1Advanced Malignant Tumors(Stage IA-IB)OncologyJun 2026
NCT06532539Cadonilimab (AK104)Phase 2Endometrial NeoplasmsOncologyAug 2026
NCT06762080Cadonilimab (AK104)Phase 1Leptomeningeal MetastasisOncologyOct 2026
NCT06341335Cadonilimab (AK104)Phase 3Gastric and Gastroesophageal Junction AdenocarcinomaOncologyNov 2026
NCT05644379Cadonilimab (AK104)Phase 1Advanced Hepatocellular Carcinoma That Has Failed at Least One Prior Systemic TherapyOncologyNov 2026
NCT06341335pulocimab (AK109)Phase 3Gastric and Gastroesophageal Junction AdenocarcinomaOncologyNov 2026
NCT06438822Cadonilimab (AK104)Phase 2CholangiocarcinomaOncologyNov 2026
NCT07266493Envafolimab (AK112)Phase 2Esophageal Squamous Cell CarcinomaOncologyDec 2026
NCT05926700Cadonilimab (AK104)Phase 2Soft Tissue SarcomaOncologyDec 2026
NCT06767527Envafolimab (AK112)Phase 3Triple-Negative Breast Cancer (TNBC)OncologyDec 2026
NCT04736823Envafolimab (AK112)Phase 2NSCLCOncologyDec 2026
NCT05689853Envafolimab (AK112)Phase 1Solid Tumor, AdultOncologyDec 2026
NCT05689853AK119Phase 1Solid Tumor, AdultOncologyDec 2026
NCT04556253Cadonilimab (AK104)Phase 2MSI-H/dMMR Gastric Carcinoma and Colorectal CancerOncologyDec 2026
NCT05687851Cadonilimab (AK104)Phase 2Locally Advanced Cervical CancerOncologyDec 2026
NCT06943820AK129Phase 1Non-small Cell Lung Cancer Stage IIIB/IVOncologyDec 2026
NCT04974398Penpulimab (AK105)Phase 3Nasopharyngeal CarcinomaOncologyDec 2026
NCT05227664Envafolimab (AK112)Phase 2Metastatic Triple-negative Breast CancerOncologyDec 2026
NCT06646055Envafolimab (AK112)Phase 1Metastatic Pancreatic Ductal AdenocarcinomaOncologyDec 2026
NCT07243626Envafolimab (AK112)Phase 2Soft Tissue SarcomaOncologyDec 2026
NCT06321081Envafolimab (AK112)Phase 2RAS MutationOncologyDec 2026
NCT05227664AK117Phase 2Metastatic Triple-negative Breast CancerOncologyDec 2026
NCT06646055Cadonilimab (AK104)Phase 1Metastatic Pancreatic Ductal AdenocarcinomaOncologyDec 2026
NCT06467500Cadonilimab (AK104)Phase 2Non-small Cell Lung CancerOncologyDec 2026
NCT05840016Envafolimab (AK112)Phase 3Advanced Squamous Non Small Cell Lung CancerOncologyDec 2026
NCT05499390Envafolimab (AK112)Phase 3Advanced Non-small-cell Lung CancerOncologyDec 2026
NCT05229497Envafolimab (AK112)Phase 1Advanced Malignant TumorsOncologyDec 2026
NCT07852091Envafolimab (AK112)Phase 2Chronic Hepatitis BInfectious diseaseDec 2026
NCT05959356Envafolimab (AK112)Phase 2Metastatic Colorectal CancerOncologyDec 2026
NCT05959356Envafolimab (AK112)Phase 2Metastatic Colorectal CancerOncologyDec 2026
NCT05397769Envafolimab (AK112)Phase 2Locally Advanced Nasopharyngeal CarcinomaOncologyDec 2026
NCT05229497AK117Phase 1Advanced Malignant TumorsOncologyDec 2026
NCT06218810Cadonilimab (AK104)Phase 2Metastatic Colorectal CancerOncologyDec 2026
NCT06587425Cadonilimab (AK104)Phase 2Gastric or Gastroesophageal Junction AdenocarcinomaOncologyDec 2026
NCT06769971Cadonilimab (AK104)Phase 2Small Cell Lung CancerOncologyDec 2026
NCT07104149Cadonilimab (AK104)Phase 2Female, Age ≥ 18 Years OldOncologyDec 2026
NCT06728631Cadonilimab (AK104)Phase 2Oral Cavity CancerOncologyDec 2026
NCT06477523Cadonilimab (AK104)Phase 1SCLC, Extensive StageOncologyDec 2026

The 60 nearest readouts of 196 trials; the rest in the app.

From the company's SEC filings

Complete response letters from FDA

Targets

PDCD1 (5) NT5E (2) CD274 (1) CD47 (1) CTLA4 (1) TROP2 (1) NECTIN4 (1) PD-L2 (1) LAG3 (1) VEGFA (1)

Companies with the same targets

AstraZeneca Sichuan Baili Pharmaceutical Shanghai Henlius Biotech Innovent Biologics (Suzhou) Pfizer Shenyang Sunshine Pharmaceutical Ono Pharmaceutical Mabwell (Shanghai) Bioscience GSK Bio-Thera Solutions

Companies built like this

Shanghai Henlius Biotech Shenyang Sunshine Pharmaceutical Sichuan Baili Pharmaceutical Mabwell (Shanghai) Bioscience Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.